Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place from January 13-16, 2025, in San Francisco, CA. Dr. Pravin U. Dugel, Executive Chairman, President and CEO, will deliver the company's presentation on Monday, January 13, 2025, at 5:15 PM PT.
The presentation will be accessible through a live webcast on the Events and Presentations section of the company's Investor Relations webpage. Ocular Therapeutix is a biopharmaceutical company focused on developing and commercializing innovative therapies for retinal diseases and other eye conditions, with the mission of improving real-world vision.
Ocular Therapeutix (NASDAQ: OCUL) ha annunciato la sua partecipazione al 43° Conference Annuale J.P. Morgan Healthcare. La conferenza si svolgerà dal 13 al 16 gennaio 2025, a San Francisco, CA. Dr. Pravin U. Dugel, Presidente Esecutivo, Presidente e CEO, presenterà l'azienda lunedì 13 gennaio 2025, alle 17:15 PT.
La presentazione sarà accessibile tramite un webcast dal vivo nella sezione Eventi e Presentazioni della pagina delle Relazioni con gli Investitori dell'azienda. Ocular Therapeutix è un'azienda biofarmaceutica focalizzata nello sviluppo e nella commercializzazione di terapie innovative per le malattie retiniche e altre condizioni oculari, con la missione di migliorare la visione nella vita reale.
Ocular Therapeutix (NASDAQ: OCUL) ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. La conferencia tendrá lugar del 13 al 16 de enero de 2025, en San Francisco, CA. Dr. Pravin U. Dugel, Presidente Ejecutivo, Presidente y CEO, presentará la compañía el lunes 13 de enero de 2025, a las 5:15 PM PT.
La presentación será accesible a través de una transmisión en vivo en la sección de Eventos y Presentaciones de la página web de Relaciones con Inversores de la compañía. Ocular Therapeutix es una empresa biofarmacéutica centrada en el desarrollo y la comercialización de terapias innovadoras para enfermedades de la retina y otras condiciones oculares, con la misión de mejorar la visión en el mundo real.
Ocular Therapeutix (NASDAQ: OCUL)는 제43회 J.P. Morgan Healthcare 연례 컨퍼런스에 참가한다고 발표했습니다. 이 컨퍼런스는 2025년 1월 13일부터 16일까지 캘리포니아주 샌프란시스코에서 개최됩니다. Dr. Pravin U. Dugel, 회장 겸 CEO, 는 2025년 1월 13일 월요일 오후 5시 15분 PT에 회사의 발표를 진행합니다.
발표는 회사 투자자 관계 웹페이지의 이벤트 및 발표 섹션을 통해 라이브 웹캐스트로 접근할 수 있습니다. Ocular Therapeutix는 망막 질환 및 기타 안과적 상태에 대한 혁신적인 치료법을 개발하고 상용화하는 데 초점을 맞춘 생물 제약 회사이며, 실제 비전 개선을 목표로 하고 있습니다.
Ocular Therapeutix (NASDAQ: OCUL) a annoncé sa participation à la 43e conférence annuelle J.P. Morgan Healthcare. La conférence se déroulera du 13 au 16 janvier 2025 à San Francisco, CA. Dr. Pravin U. Dugel, Président Exécutif, Président et CEO, présentera l'entreprise le lundi 13 janvier 2025 à 17h15 PT.
La présentation sera accessible par le biais d'un webcast en direct dans la section Événements et Présentations de la page Web des Relations Investisseurs de l'entreprise. Ocular Therapeutix est une entreprise biopharmaceutique axée sur le développement et la commercialisation de thérapies innovantes pour les maladies rétiniennes et d'autres conditions oculaires, avec pour mission d'améliorer la vision dans le monde réel.
Ocular Therapeutix (NASDAQ: OCUL) hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Konferenz bekannt gegeben. Die Konferenz findet vom 13. bis 16. Januar 2025 in San Francisco, Kalifornien, statt. Dr. Pravin U. Dugel, Exekutivvorsitzender, Präsident und CEO, wird die Unternehmenspräsentation am Montag, den 13. Januar 2025, um 17:15 Uhr PT halten.
Die Präsentation wird über einen Live-Stream im Bereich Veranstaltungen und Präsentationen der Investor-Relations-Website des Unternehmens zugänglich sein. Ocular Therapeutix ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Vermarktung innovativer Therapien für Netzhauterkrankungen und andere Augenleiden spezialisiert hat, mit der Mission, die Sicht im wirklichen Leben zu verbessern.
- None.
- None.
BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference to be held January 13-16, 2025 in San Francisco, CA.
43rd Annual J.P. Morgan Healthcare Conference Presentation Details
Presentation Date: Monday, January 13, 2025
Presentation Time: 5:15 PM PT
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: San Francisco, CA
The live presentation can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
When is Ocular Therapeutix (OCUL) presenting at the J.P. Morgan Healthcare Conference 2025?
Who will present for Ocular Therapeutix (OCUL) at the 2025 J.P. Morgan Healthcare Conference?
How can investors access Ocular Therapeutix's (OCUL) J.P. Morgan Healthcare Conference presentation?
What is the focus area of Ocular Therapeutix (OCUL)?
